BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Temozolomide: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Sapience Therapeutics, Hangzhou Hanx Biopharmaceuticals, Ltd., Eli Lilly and Company, Philogen S.p.A., BPGbio, JenKem Technology Co., Ltd., BeOne Medicines. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | Sapience Therapeutics | NCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain | active not recruiting | 125 |
| 2026-12-31 est. | P1/P2 | Hangzhou Hanx Biopharmaceuticals, Ltd. | NCT06703255 A Phase 2 Study of HX301 in Patients with High-grade Giloma | Glioma | recruiting | 72 |
| 2027-02 est. | P2 | Eli Lilly and Company LLY | NCT06413706 A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Glioma | active not recruiting | 45 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P1/P2 | Philogen S.p.A. | NCT04443010 Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma | Glioblastoma | recruiting | 226 |
| 2026-08-25 est. | P2 | BPGbio | NCT04752813 A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | Glioblastoma; Glioblastoma Multiforme | active not recruiting | 50 |
| 2026-08-16 est. | P2 | JenKem Technology Co., Ltd. | NCT06595186 JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) | Glioblastoma Multiforme (GBM) | recruiting | 25 |
| 2026-05-23 | P3 | BeOne Medicines ONC | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | Advanced Malignancies | completed | 404 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.